Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Pirfenidone Tablet and Capsule
NCT02525484Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Roche. Primary endpoints: Peak Plasma Concentration at 11 days, Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time of the Last Quantifiable Concentration at 11 days and 1 more. Started Aug 2015; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02525484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525484.